NMS · Biotechnology

IMVT (IMVT) Stock

$39.24 +1.91% NMS: IMVT Healthcare

Valuation

MetricValue
Price$39.24
Market Cap$8.06B
P/E Ratio-11.09
P/B Ratio5.91
P/S Ratio0.00
EPS (TTM)$-2.67
52-Week High$41.09
52-Week Low$13.52
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-69.35%
ROA-41.33%
ROCE-61.95%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio15.74

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-108.0M$-156.0M$-208.0M$-270.0M$-438.0M
Net Profit$-107.0M$-157.0M$-211.0M$-259.0M$-414.0M
EPS$-1.22$-1.43$-1.71$-1.88$-2.73
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$412.0M$516.0M$406.0M$667.0M$776.0M
Total Liabilities$21.0M$46.0M$43.0M$49.0M$69.0M
Cash$400.0M$494.0M$377.0M$635.0M$714.0M
Borrowings$3.0M$2.0M$1.0M$0$0

Latest News

Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing MT Newswires · Jun 29, 2026 Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing MT Newswires · Jun 29, 2026 Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? Zacks · Jun 19, 2026 Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight PR Newswire · Jun 18, 2026 Immunovant Stock Gains 12.4% in a Month: What's Driving It? Zacks · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-83.0M$-106.0M$-188.0M$-214.0M$-376.0M
Investing Cash Flow$0$-1.0M$0$-1.0M$-2.0M
Financing Cash Flow$0$200.0M$0$0$4.0M
Net Cash Flow$300.0M$94.0M$-117.0M$259.0M$79.0M
Free Cash Flow$-84.0M$-106.0M$-188.0M$-215.0M$-377.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-4.28
EV / EBITDA-9.94
FCF Yield-7.26%
Quick Ratio15.74
Interest Coverage—
Return 1Y123.33%
Return 3Y77.42%
Return 5Y289.46%

Ownership

Insiders Held56.56%
Institutions Held54.64%
Institutions Float Held125.76%
Institutional HolderSharesReport Date
FMR, LLC16,947,8882026-03-31
Deep Track Capital, Lp11,526,9712026-03-31
Blackrock Inc.6,574,4972026-03-31
Baker Bros. Advisors, LP5,457,8812026-03-31
State Street Corporation4,537,9292026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $29.21 +2.67% 8.94 $5.00B 0.00%
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
DYN $25.97 +2.89% -6.05 $4.85B 0.00%
KYMR $103.40 -3.37% -23.01 $8.51B 0.00%

About IMVT

IMVT is led by CEO Eric Venker, employs 315 people, headquartered in Durham, US, publicly traded since 2019.

IMVT stock trades at $39.24 with a market capitalization of $8.06B. The stock is valued at a price-to-earnings (P/E) ratio of -11.09, price-to-book of 5.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $13.52 and $41.09, and currently trades 4.5% below its 52-week high.

On profitability, IMVT generates a return on equity (ROE) of -69.35%, return on capital employed of -61.95%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides